Searching for clues: can blood tests predict who survives liver cancer?
NCT ID NCT06796114
Summary
This study aims to find biological markers in the blood that can predict how well liver cancer patients respond to a specific immunotherapy combination (tremelimumab and durvalumab). Researchers will follow 120 patients with advanced liver cancer who are receiving this treatment as part of their regular care. The goal is to identify which patients are most likely to benefit from this therapy, helping doctors make better treatment decisions.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CH de Chalon sur Saône
RECRUITINGChalon-sur-Saône, France
Contact
-
CH de Mulhouse
RECRUITINGMulhouse, France
Contact
-
CHU Grenoble
RECRUITINGGrenoble, France
Contact
-
CHU Poitiers
NOT_YET_RECRUITINGPoitiers, France
Contact
-
CHU de Besançon
RECRUITINGBesançon, France
Contact
-
CHU de Reims
NOT_YET_RECRUITINGReims, France
Contact
-
Hôpital Beaujon - APHP
RECRUITINGParis, France
Contact
-
Hôpital Henri Mondor - APHP
NOT_YET_RECRUITINGParis, France
Contact
-
Hôpital La Pitié Salpêtrière - APHP
RECRUITINGParis, France
Contact
-
ICANS
NOT_YET_RECRUITINGStrasbourg, France
Contact
Conditions
Explore the condition pages connected to this study.